Survey reveals Gamunex as preferred IGIV therapy among neurologists

Talecris Biotherapeutics, Inc., today announced results of a new survey showing that Gamunex® (Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified) is the preferred immune globulin intravenous (IGIV) among neurologists who indicated a brand preference. In the survey, conducted online by Harris Interactive® on behalf of Talecris, neurologists selected Gamunex over four times more often than all other available liquid IGIV therapies, with a statistically significant margin (p<0.05).

Gamunex has the broadest set of FDA-approved indications for any liquid IGIV, and it is the only therapy on the market approved to treat chronic inflammatory demyelinating polyneuropathy (CIDP), a debilitating neurologic condition that can lead to severe impairment of motor skills. Neurologists, the specialists who treat CIDP, prescribe more grams of IGIV than any other physician specialty.

"Our investment in a significant clinical trial to treat CIDP with Gamunex resulted in the first and only FDA-approved treatment for CIDP. We are particularly pleased that the clinical trial provided outcomes data for neurologists to make informed treatment decisions," said Larry Stern, chairman and CEO of Talecris Biotherapeutics. "The Harris Interactive study shows that our educational efforts are already having a positive impact on brand choice, and we look forward to providing further educational support about the clinical use of Gamunex."

SOURCE Talecris Biotherapeutics, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
A case for updating COVID vaccines with beta variant spike sequences